Literature DB >> 2736397

Opiate and serotonergic mechanisms of stimulation-produced analgesia within the periaqueductal gray.

D S Nichols1, B E Thorn, G G Berntson.   

Abstract

These studies investigated the distribution of analgesia-producing sites within the periaqueductal gray (PAG), and their potential reversal by naloxone and methysergide. The PAG is not differentiable in its ability to elicit stimulation-produced analgesia (SPA) until the point of stimulation is caudal to the dorsal raphe nucleus, where analgesia was not obtained. Naloxone, however, was found to have a differential effect at specific loci, significantly reducing SPA from ventral but not dorsal sites. In contrast, methysergide was effective in reversing analgesia both at ventral and dorsal sites. The site of stimulation was critical to whether motor effects were elicited: Motor effects accompanied by analgesia were most often produced rostrally, while motor effects without analgesia were most frequently produced in the middle PAG. Null effects for both motor activity and analgesia were obtained from caudal PAG sites.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2736397     DOI: 10.1016/0361-9230(89)90091-9

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  3 in total

1.  Effect of the blockade of mu1-opioid and 5HT2A-serotonergic/alpha1-noradrenergic receptors on sweet-substance-induced analgesia.

Authors:  E C C Rebouças; E N Segato; R Kishi; R L Freitas; M Savoldi; S Morato; N C Coimbra
Journal:  Psychopharmacology (Berl)       Date:  2004-12-10       Impact factor: 4.530

2.  Involvement of brain serotonergic system in the antinociceptive action of acetylsalicylic acid in the rat.

Authors:  L A Pini; M Sandrini; G Vitale
Journal:  Inflamm Res       Date:  1995-01       Impact factor: 4.575

3.  Study on the Antinociceptive Effects of Herba Epimedium in Mice.

Authors:  Jiang-Hong Sun; Xin-Jie Ruan; Li-Na Wang; Shuang Liang; Xin-Ping Li
Journal:  Evid Based Complement Alternat Med       Date:  2015-06-11       Impact factor: 2.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.